Which GLP-1 Agonist Is Most Effective for Glycemic Control and Weight Loss?

In a meta-analysis, tirzepatide ranked first, and semaglutide was second, for both indications among FDA-approved agents.

Six glucagon-like peptide-1 (GLP-1) receptor agonists are U.S. FDA approved for managing diabetes; three of these also have been approved for obesity and overweight. However, few trials have compared different GLP-1 receptor agonists. Now, researchers have conducted a network meta-analysis of 76 randomized trials of approved and investigational GLP-1 receptor agonists compared with placebo or each other; 39,000 adults with type 2 diabetes, followed for ≥12 weeks, were included.

Tirzepatide, a combined GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, was the most-effective approved agent for both indications, with mean differences of −2.1% in glycosylated hemoglobin (HbA_1c), −56 mg/dL in fasting blood glucose, an…

Reviewing Author

Bruce Soloway, MD

Disclosures

Editorial BoardsNew RoAR News (http://www.newroarnews.org)

Bruce Soloway, MD

Disclosures

Editorial BoardsNew RoAR News (http://www.newroarnews.org)

Which GLP-1 Agonist Is Most Effective for Glycemic Control and Weight Loss?

Topics

Reviewing Author